Indication: Type 2 Diabetes (T2D)

Efficacy and safety of oral semaglutide versus placebo both in combination with metformin and/or basal insulin in children and adolescents with type 2 diabetes

Sub-indication: Type 2 Diabetes (T2D)

Drug Study

Principal Investigator: Kupper Wintergerst, M.D.
Norton Children's Endocrinology, affiliated with the UofL School of Medicine

Sponsor: Novo Nordisk, Inc.

Search our entire site.